These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 35776741)

  • 1. Efficacy and safety of saroglitazar for the management of dyslipidemia: A systematic review and meta-analysis of interventional studies.
    Chhabra M; Vidyasagar K; Gudi SK; Sharma J; Sharma R; Rashid M
    PLoS One; 2022; 17(7):e0269531. PubMed ID: 35776741
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Saroglitazar, a PPAR-α/γ Agonist, for Treatment of NAFLD: A Randomized Controlled Double-Blind Phase 2 Trial.
    Gawrieh S; Noureddin M; Loo N; Mohseni R; Awasty V; Cusi K; Kowdley KV; Lai M; Schiff E; Parmar D; Patel P; Chalasani N
    Hepatology; 2021 Oct; 74(4):1809-1824. PubMed ID: 33811367
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and Efficacy of Saroglitazar in Nonalcoholic Fatty Liver Patients With Diabetic Dyslipidemia-A Prospective, Interventional, Pilot Study.
    Rajesh NA; Drishya L; Ambati MMR; Narayanan AL; Alex M; R KK; Abraham JJ; Vijayakumar TM
    J Clin Exp Hepatol; 2022; 12(1):61-67. PubMed ID: 35068786
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual PPRαϒ Agonists for the Management of Dyslipidemia: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.
    Menezes Junior ADS; Oliveira VMR; Oliveira IC; de Sousa AM; Santana AJP; Carvalho DPC; Paro Piai RF; Matos FH; de Paiva AM; Reis GBB
    J Clin Med; 2023 Aug; 12(17):. PubMed ID: 37685742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Observational study to evaluate the safety and efficacy of saroglitazar in Indian diabetic dyslipidemia patients.
    Shetty SR; Kumar S; Mathur RP; Sharma KH; Jaiswal AD
    Indian Heart J; 2015; 67(1):23-6. PubMed ID: 25820046
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Saroglitazar, a Dual PPAR α/γ Agonist, Improves Atherogenic Dyslipidemia in Patients With Non-Cirrhotic Nonalcoholic Fatty Liver Disease: A Pooled Analysis.
    Siddiqui MS; Parmar D; Sheikh F; Sarin SK; Cisneros L; Gawrieh S; Momin T; Duseja A; Sanyal AJ
    Clin Gastroenterol Hepatol; 2023 Sep; 21(10):2597-2605.e2. PubMed ID: 36731585
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of saroglitazar in managing hypertriglyceridemia in type-2 diabetes: A meta-analysis.
    Dutta D; Bhattacharya S; Surana V; Aggarwal S; Singla R; Khandelwal D; Sharma M
    Diabetes Metab Syndr; 2020; 14(6):1759-1768. PubMed ID: 32937280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Study of Saroglitazar in Treatment Of Pre-diabetes with Dyslipidemia: STOP-D.
    Bhosle D; Bhosle V; Bobde J; Bhagat A; Shaikh H; Kadam R
    J Assoc Physicians India; 2018 Mar; 66(3):14-7. PubMed ID: 30341861
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Safety of Saroglitazar in Patients with Cardiometabolic Diseases: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Durga DR; Mounika N; Mudimala P; Adela R
    Clin Drug Investig; 2022 Dec; 42(12):1049-1064. PubMed ID: 36329293
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Prospective, Multicentre, Open-Label Single-Arm Exploratory Study to Evaluate Efficacy and Safety of Saroglitazar on Hypertriglyceridemia in HIV Associated Lipodystrophy.
    Deshpande A; Toshniwal H; Joshi S; Jani RH
    PLoS One; 2016; 11(1):e0146222. PubMed ID: 26789842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of saroglitazar in the treatment of non-alcoholic fatty liver disease or non-alcoholic steatohepatitis: A systematic review and meta-analysis.
    Bandyopadhyay S; Samajdar SS; Das S
    Clin Res Hepatol Gastroenterol; 2023 Aug; 47(7):102174. PubMed ID: 37380128
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Erosive esophagitis associated with metabolic syndrome, impaired liver function, and dyslipidemia.
    Loke SS; Yang KD; Chen KD; Chen JF
    World J Gastroenterol; 2013 Sep; 19(35):5883-8. PubMed ID: 24124334
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dyslipidemia and its association with meibomian gland dysfunction.
    Braich PS; Howard MK; Singh JS
    Int Ophthalmol; 2016 Aug; 36(4):469-76. PubMed ID: 26515235
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Multicenter Prospective Hospital-based Cohort Study on the Efficacy and Safety of Pitavastatin.
    Shehab A; Elnour AA; Bhagavathula AS; Kurian JP; Hassan G; AlZaabi S; Gilbert H; Al-Rasadi K
    Curr Diabetes Rev; 2021; 17(7):e122820189541. PubMed ID: 33371852
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of purslane on blood lipids and glucose: A systematic review and meta-analysis of randomized controlled trials.
    Hadi A; Pourmasoumi M; Najafgholizadeh A; Kafeshani M; Sahebkar A
    Phytother Res; 2019 Jan; 33(1):3-12. PubMed ID: 30281177
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of colesevelam and niacin on low-density lipoprotein cholesterol and glycemic control in subjects with dyslipidemia and impaired fasting glucose.
    Davidson MH; Rooney M; Pollock E; Drucker J; Choy Y
    J Clin Lipidol; 2013; 7(5):423-32. PubMed ID: 24079283
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Multicenter, Prospective, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Saroglitazar 2 and 4 mg Compared to Pioglitazone 45 mg in Diabetic Dyslipidemia (PRESS V).
    Pai V; Paneerselvam A; Mukhopadhyay S; Bhansali A; Kamath D; Shankar V; Gambhire D; Jani RH; Joshi S; Patel P
    J Diabetes Sci Technol; 2014 Jan; 8(1):132-141. PubMed ID: 24876549
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Meta-analysis of the Efficacy and Safety of Adjunctive Rosuvastatin for Dyslipidemia in Patients with Schizophrenia.
    Zheng W; Yang W; Zhang QE; Yang XH; Cai DB; Hu JQ; Ungvari GS; Ng CH; De Hert M; Ning YP; Xiang YT
    Shanghai Arch Psychiatry; 2018 Feb; 30(1):4-11. PubMed ID: 29719353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of mipomersen in treatment of dyslipidemia: a meta-analysis of randomized controlled trials.
    Panta R; Dahal K; Kunwar S
    J Clin Lipidol; 2015; 9(2):217-25. PubMed ID: 25911078
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Efficacy of
    Yang K; Kim HH; Shim YR; Song MJ
    Nutrients; 2023 Jan; 15(3):. PubMed ID: 36771427
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.